Evaluation of the Japanese Metabolic Syndrome Risk Score (JAMRISC): a newly developed questionnaire used as a screening tool for diagnosing metabolic syndrome and insulin resistance in Japan.

Autor: Tan, Ce, Sasagawa, Yutaka, Kamo, Ken-ichi, Kukitsu, Takehiro, Noda, Sayaka, Ishikawa, Kazuma, Yamauchi, Natsumi, Saikawa, Takashi, Noro, Takanori, Nakamura, Hajime, Takahashi, Fumihiko, Sata, Fumihiro, Tada, Mitsuhiro, Kokai, Yasuo
Zdroj: Environmental Health & Preventive Medicine; Nov2016, Vol. 21 Issue 6, p470-479, 10p
Abstrakt: Objectives: To prevent the onset of lifestyle-related diseases associated with metabolic syndrome (MetS) in Japan, research into the development of a useful screening method is strongly desired. We developed a new screening questionnaire (JAMRISC) utilizing a logistic regression model and evaluated its ability to predict the development of MetS, type 2 diabetes and other lifestyle-related diseases in Japanese populace. Methods: JAMRISC questionnaire was sent to 1,850 individuals in Rumoi, a small city in Hokkaido. We received a total of 1,054 valid responses. To maximize the target individuals accurately diagnosed with MetS, logistic regression analysis was used to generate a unique metabolic syndrome score calculation formula as taking into consideration the clinical relevance of each question item as individual coefficients. Results: The results of our comparative research utilizing both JAMRISC and Finnish Diabetes Risk Score (FINDRISC) questionnaires revealed the usefulness of JAMRISC for its ability to detect risks for MetS, pre-MetS, diabetes, and pre-diabetes. Study of disease risk detection via JAMRISC questionnaire targeting the 4283 residents of Rumoi indicated a high detection rate for pre-MetS (98.8 %), MetS (94.2 %), pre-diabetes (85.1 %) and type 2 diabetes (94.9 %). In addition, JAMRISC was useful not only as a MetS risk score test, but also as a screening tool for diagnosing insulin resistance. Conclusions: JAMRISC questionnaire is a useful instrument for the detection of early risk of not only MetS and type 2 diabetes but also insulin resistance. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz: